By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

(Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants ...

Novo Nordisk submitted the 7.2 mg dose of Wegovy to offer a tailored option for people with obesity who need greater weight loss support.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on Novo Nordisk A/S (NYSE:NVO), maintaining a price target of 610 Danish ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Novo Nordisk’s Wegovy® is one of two branded, FDA approved, GLP-1s. On February 21, 2025, the FDA determined that the semaglutide product shortage had been resolved.

Hims & Hers said in return that Novo Nordisk was trying to pressure it to steer patients to Wegovy regardless of whether it was the best option for patients.